Focal Interest
Focal Interest

Pharmaceutical industry and healthcare

External reference: https://openalex.org/T11649

  1. Private hospital managers back legal regulation of healthcare advertising
    Qualitative study of private hospital managers' perspectives on healthcare advertising bans, regulatory gaps, and ethical concerns in Turkey
  2. Industry payments were linked to more brand-name MS prescribing
    Pharmaceutical payments to clinicians correlated with reduced generic prescribing for MS medications, increasing costs for patients and the healthcare system overall.
  3. Most favored nation drug pricing may lower industry research revenue
    Analysis of most favored nation drug pricing as policy mechanism to reduce international price disparities and effects on pharmaceutical research investment and innovation.
  4. Zuranolone was approved for postpartum depression, not major depressive disorder
    Analysis of zuranolone approval reveals how fast-track designations and reduced evidentiary thresholds in drug regulation may inadequately balance innovation with public health protection.
  5. Principles-based authorship guidance is proposed for science
    Framework for responsible authorship practices anchored in transparency, credit, and accountability across research institutions, journals, and funding organizations
  6. Private equity investment in emergency medicine raises ethical tensions
    Concept review examining private equity investment in emergency medicine, identifying conflicts between profit maximization and clinical ethics alongside regulatory gaps and research needs.
  7. Review describes peer review denials, burdens, and navigation
    Comprehensive review of insurance peer review processes, examining how prior authorization and peer-to-peer reviews impact physicians, patients, and healthcare quality.
  8. Rivaroxaban controversy linked to synthetic certainty
    Analysis of regulatory closure and synthetic certainization in rivaroxaban authorization, examining how institutional power consolidated therapeutic claims despite device defects.
  9. Layered PPIE broadened involvement in the RETURN dental study
    Structured layered approach to patient and public involvement in health inequalities research combining experienced contributors with grassroots engagement to enhance socio-economic representation.
  10. Turkish drug recalls were driven by contamination, sterility, and safety issues
    Systematic analysis of 133 drug recalls by Turkish regulatory agency 2018-2024, identifying 14 recall reasons with Class A and B classifications predominating.
  11. Drug shortages create risks in obstetric care
    Clinical analysis of drug shortages in obstetric care addressing causation, prediction, and systematic response mechanisms for healthcare institutions.
  12. Meloxicam approval in cats is questioned over kidney risk and missing trial data
    Examine injectable meloxicam approval for cats, regulatory data discrepancies, acute kidney injury risks, and pharmaceutical sponsorship conflicts in veterinary medicine.
  13. FAERS data show post-marketing adverse event patterns with casimersen
    Pharmacovigilance analysis of casimersen adverse event reporting patterns using FAERS database with characterization of preferred terms, organ systems, and time-to-onset distributions.
  14. Contact information linked to tobacco coupon receipt and use
    Study examining tobacco coupon receipt, redemption, and cross-product marketing among U.S. adult tobacco users, documenting tobacco industry engagement strategies and subsequent purchase behavior.